1. Home
  2. BY vs GLUE Comparison

BY vs GLUE Comparison

Compare BY & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BY

Byline Bancorp Inc.

HOLD

Current Price

$32.51

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$18.56

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BY
GLUE
Founded
1914
2019
Country
United States
United States
Employees
N/A
147
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
BY
GLUE
Price
$32.51
$18.56
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$33.50
$29.50
AVG Volume (30 Days)
157.7K
912.4K
Earning Date
04-22-2026
01-01-0001
Dividend Yield
1.51%
N/A
EPS Growth
3.00
N/A
EPS
2.12
N/A
Revenue
N/A
$75,622,000.00
Revenue This Year
$17.06
$84.02
Revenue Next Year
$2.84
N/A
P/E Ratio
$15.27
$72.42
Revenue Growth
N/A
N/A
52 Week Low
$22.63
$3.50
52 Week High
$33.89
$25.77

Technical Indicators

Market Signals
Indicator
BY
GLUE
Relative Strength Index (RSI) 54.16 44.19
Support Level $32.00 $17.68
Resistance Level $33.89 $18.66
Average True Range (ATR) 0.83 1.09
MACD -0.18 -0.10
Stochastic Oscillator 43.46 35.16

Price Performance

Historical Comparison
BY
GLUE

About BY Byline Bancorp Inc.

Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: